NCT04801888View on ClinicalTrials.gov

Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
COVID-19Influenza
Interventions
BIOLOGICAL

Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 0 or day 28.

The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.

BIOLOGICAL

Two doses of inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 and one dose Quadrivalent Influenza Vaccine on day 14.

The inactivated SARS-CoV-2 vaccine was manufactured by Sinovac Research \& Development Co., Ltd., with a antigen content of 600SU/0.5ml. The Quadrivalent Influenza Vaccine manufactured by Sinovac Biotech Co.,Ltd. including 4 antigens H1N1, H3N2, BV and BY, 15μg for each, 0.5ml per dose.

Trial Locations (1)

324300

Kaihua county Center for Disease Control and Prevention, Quzhou

All Listed Sponsors
lead

Sinovac Research and Development Co., Ltd.

INDUSTRY

NCT04801888 - Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine | Biotech Hunter | Biotech Hunter